Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective study of combining vedolizumab with other biologics or with tofacitinib in patients with Inflammatory Bowel Disease

Next Previous
Trial Profile

Retrospective study of combining vedolizumab with other biologics or with tofacitinib in patients with Inflammatory Bowel Disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vedolizumab (Primary) ; Adalimumab; Tofacitinib; Ustekinumab
  • Indications Colitis; Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 26 Oct 2022 Results assessing Long-Term Outcomes of Treatment With and De-Escalation From a Combination of Vedolizumab and Another Biologic or Tofacitinib for Inflammatory Bowel Disease presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
  • 22 Dec 2020 New trial record
  • 28 Oct 2020 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top